Susini T, Baldi F, Howard C M, Baldi A, Taddei G, Massi D, Rapi S, Savino L, Massi G, Giordano A
Obstetrics and Gynecology Department, University of Florence, Careggi Hospital, Italy.
J Clin Oncol. 1998 Mar;16(3):1085-93. doi: 10.1200/JCO.1998.16.3.1085.
The retinoblastoma gene is the prototype of tumor-suppressor genes and has been shown to be involved in the pathogenesis and progression of several human malignancies. In this study, we determined the relation between the expression of a newly discovered retinoblastoma-related gene Rb2/p130 and outcome in patients with endometrial carcinoma.
pRb2/p130 expression was determined immunohistochemically in specimens of endometrial carcinoma (stages I to IV) from 100 patients who underwent surgery as the first treatment. The pRb2/p130 status was analyzed in relation to the length of disease-free survival and disease-specific survival.
Decreased levels of pRb2/p130 in endometrial cancer cells was significantly associated with a decreased probability of remaining disease-free after treatment (P = .003) and with decreased probability of survival (P < .0001). In a multivariate analysis, pRb2/p130 status (P = .004), tumor stage (P = .009), and ploidy status (P = .02) were independent predictors of clinical outcome. The risk of dying of disease was increased substantially (risk ratio, 4.91; 95% confidence interval, 1.66 to 14.54) among patients with decreased levels of pRb2/p130 in tumor cells.
In patients with endometrial carcinoma who did not receive radiotherapy or chemotherapy before surgery, the presence of decreased levels of pRb2/p130 in tumor cells is associated with a significantly increased risk of recurrence and death of disease, independent of tumor stage and ploidy status.
视网膜母细胞瘤基因是肿瘤抑制基因的原型，已被证明与多种人类恶性肿瘤的发病机制和进展有关。在本研究中，我们确定了新发现的视网膜母细胞瘤相关基因Rb2/p130的表达与子宫内膜癌患者预后之间的关系。
对100例接受手术作为首次治疗的子宫内膜癌（I至IV期）患者的标本进行免疫组织化学检测，以确定pRb2/p130的表达。分析pRb2/p130状态与无病生存期和疾病特异性生存期的关系。
子宫内膜癌细胞中pRb2/p130水平降低与治疗后无病概率降低（P = 0.003）和生存概率降低（P < 0.0001）显著相关。在多变量分析中，pRb2/p130状态（P = 0.004）、肿瘤分期（P = 0.009）和倍体状态（P = 0.02）是临床结局的独立预测因素。肿瘤细胞中pRb2/p130水平降低的患者死于疾病的风险大幅增加（风险比，4.91；95%置信区间，1.66至14.54）。
在术前未接受放疗或化疗的子宫内膜癌患者中，肿瘤细胞中pRb2/p130水平降低与疾病复发和死亡风险显著增加相关，与肿瘤分期和倍体状态无关。
